While the New York Times reports Lenacapavir's arrival amid U.S. aid reductions, deeper analysis reveals how PEPFAR funding cuts since 2025 have dismantled community outreach networks critical for twice-yearly injections, patterns echoing the 2010s dolutegravir rollout delays in sub-Saharan Africa. The PURPOSE 1 trial (RCT, n=5,322 women, no major conflicts disclosed beyond Gilead sponsorship) demonstrated 100% efficacy in cisgender women yet highlighted adherence barriers in low-resource settings absent from initial coverage. Observational data from Zambia's 2023 HIV cohort studies (sample ~12,000, retrospective design) show only 34% retention for long-acting agents due to transport and stigma, issues the NYT underplays. Synthesizing these with a 2024 Lancet Global Health review (observational, multi-country, n=48,000) underscores that aid hollowing disproportionately affects rural women, perpetuating disparities beyond drug access to include cold-chain failures and provider training deficits missed in surface reporting.